Abstract
Background: We have previously reported that a quinolizidine natural product, aloperine, and its analogs can inhibit influenza virus and/or HIV-1 at low μM concentrations.
Objective: The main goal of this study was to further optimize aloperine for improved anti-influenza virus activity.
Methods: Structural modifications have been focused on the N12 position of aloperine scaffold. Conventional chemical synthesis was used to obtain derivatives with improved antiviral activities. The anti-HIV and anti-influenza virus activities of the synthesized compounds were determined using an MT4 cell-based HIV-1 replication assay and an anti- influenza virus infection of MDCK cell assay, respectively.
Results: Aloperine derivatives can be classified into three activity groups: those that exhibit anti-HIV activity only, anti–influenza virus only, or activity against both viruses. Aloperine optimized for potent anti-influenza activity often lost anti-HIV-1 activity, and vice versa. Compound 19 inhibited influenza virus PR8 replication with an IC50 of 0.091 μM, which is approximately 160- and 60-fold more potent than aloperine and the previously reported aloperine derivative compound 3, respectively.
Conclusion: The data suggest that aloperine is a privileged scaffold that can be modified to become a selective antiviral compound with markedly improved potency against influenza virus or HIV-1.
Keywords: Aloperine, privileged scaffold, influenza A virus, HIV-1, quinolizidine derivatives, HIV-1 inhibitors.
Current Medicinal Chemistry
Title:Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors
Volume: 28 Issue: 24
Author(s): Zhao Dang, Lei Zhu, Lan Xie, Kuo-Hsiung Lee, Faisal Malik, Zhijun Li, Li Huang*Chin-Ho Chen*
Affiliation:
- Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710,United States
- Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710,United States
Keywords: Aloperine, privileged scaffold, influenza A virus, HIV-1, quinolizidine derivatives, HIV-1 inhibitors.
Abstract:
Background: We have previously reported that a quinolizidine natural product, aloperine, and its analogs can inhibit influenza virus and/or HIV-1 at low μM concentrations.
Objective: The main goal of this study was to further optimize aloperine for improved anti-influenza virus activity.
Methods: Structural modifications have been focused on the N12 position of aloperine scaffold. Conventional chemical synthesis was used to obtain derivatives with improved antiviral activities. The anti-HIV and anti-influenza virus activities of the synthesized compounds were determined using an MT4 cell-based HIV-1 replication assay and an anti- influenza virus infection of MDCK cell assay, respectively.
Results: Aloperine derivatives can be classified into three activity groups: those that exhibit anti-HIV activity only, anti–influenza virus only, or activity against both viruses. Aloperine optimized for potent anti-influenza activity often lost anti-HIV-1 activity, and vice versa. Compound 19 inhibited influenza virus PR8 replication with an IC50 of 0.091 μM, which is approximately 160- and 60-fold more potent than aloperine and the previously reported aloperine derivative compound 3, respectively.
Conclusion: The data suggest that aloperine is a privileged scaffold that can be modified to become a selective antiviral compound with markedly improved potency against influenza virus or HIV-1.
Export Options
About this article
Cite this article as:
Dang Zhao, Zhu Lei, Xie Lan , Lee Kuo-Hsiung , Malik Faisal, Li Zhijun, Huang Li *, Chen Chin-Ho *, Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors, Current Medicinal Chemistry 2021; 28 (24) . https://dx.doi.org/10.2174/0929867328666201229121802
DOI https://dx.doi.org/10.2174/0929867328666201229121802 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solution-Phase Parallel Synthesis of an Isoflavone Library for the Discovery of Novel Antigiardial Agents
Combinatorial Chemistry & High Throughput Screening Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology SARS-CoV-2: Molecular Biology and Therapeutic Targets
Coronaviruses Synthesis of Specific Protein Phosphatase Inhibitors, Tautomycin and Tautomycetin toward Structure-Activity Relationship Study
Current Medicinal Chemistry Graphical Abstracts
Letters in Drug Design & Discovery Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists
Current Topics in Medicinal Chemistry Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer
Current Cancer Drug Targets Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial
Anti-Infective Agents in Medicinal Chemistry Common SAR Derived from Multiple QSAR Models on Vorinostat Derivatives Targeting HDACs in Tumor Treatment
Current Pharmaceutical Design Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease
Current Medicinal Chemistry Carbohydrate-Based Scaffolds in Drug Discovery
Mini-Reviews in Medicinal Chemistry Anti-Viral
Current Bioactive Compounds Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy
Combinatorial Chemistry & High Throughput Screening Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry The Antibacterial Activity of 1,2,3-triazole- and 1,2,4-Triazole-containing Hybrids against <i>Staphylococcus aureus</i>: An Updated Review (2020- Present)
Current Topics in Medicinal Chemistry Structure Guided Design of Biotin Protein Ligase Inhibitors for Antibiotic Discovery
Current Topics in Medicinal Chemistry New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle
Current Medicinal Chemistry Anti-Tuberculosis
Current Bioactive Compounds Quantitative Structure-Activity Relationships of Renin Inhibitors
Mini-Reviews in Medicinal Chemistry